Skip to content
‹ Back to IndustriesHealthcare

Barrow Hanley Credit Partners: Lens on Credit Series | Fed Moves Expected Impacts on Leveraged Finance Markets

Fed Moves: Expected Impacts on Leveraged Finance Markets Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies. More about Chet Paipanandiker, Portfolio Manager More about Nick Losey, Portfolio Manager

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Fed Moves: Expected Impacts on Leveraged Finance Markets

Fixed Income Portfolio Managers Chet Paipanandiker and Nick Losey provide their views on expected rates hikes by 2023 and how they will impact the financial health of high yield companies.

More about Chet Paipanandiker, Portfolio Manager

More about Nick Losey, Portfolio Manager

Video TranscriptExpand ↓

What is it that we expect for the Fed to do here when it comes to rates? And what is that probably going to do to credit markets and more specifically, leveraged finance markets? So, you know, the Fed was previously expecting to raise rates by about 75 basis points, potentially take rates to probably that 3.75 to 400 basis points in 2023. Expectations now are actually that rates come off a tad from that. In terms of the upper bound by 2023, we're probably thinking more about that 3 and 1/2 range. And really where is the Fed was thinking about more of 100 basis points of increase here at this next Fed meeting, we're actually thinking it's probably going to be closer to 75. A lot of indications on the inflation side or actually starting to turn around, whether it's the job market, early indications of stress there or even in terms of rents. While we are seeing nationwide rents rise, there are some indications that you're going to potentially see more supply, perhaps on the multifamily side, but also in terms of single family housing. Well, the spec builds out there. And so as a result, you know, our expectation is rate increases probably are not going to pace at the level they were given what expectations were in the last couple of months. So what does that mean for leveraged finance markets in terms of how balance sheets are going to handle that? So one of the better markets to look at is actually high yield because of the prevalence of data that you can actually take a look at. And so if you were to assume we kind of top out that 3 and 1/2 rate and take a look at what that does to coverage ratios, what you'll see is buy quality level across high yield. For example, with double B's, you probably see about 12% of free cash flow eaten up by rising rates. If you swing down to single B's, you actually see probably close to 24 to 25% of free cash flow eaten up with triple C's. It's a little bit different. Most of the cash flow of CCC is that free cash flow. Triple C's is actually eaten up by rate hikes, but notice at least 90% of the market or so has good resiliency in terms of rate hikes relative to free cash flow for these companies just by virtue of the double B's and the single B's. If the Fed is more aggressive on the up side and inflation does not subside in some of the numbers that we are seeing and we do see the Fed get pushed rates all the way up to 4% wanted. Do you think there would be one, an inverted yield curve, which would significantly slow the velocity of money? Now, when it comes to the direct impact on high yield, we do think that there would be really got to focus on the fundamentals. Now, high yield has really migrated to a much higher quality index than it had been in the past. In 2007, about 35% of the index was double B's. Now that's about fifth, a little over 50% And so when we step back and look at just the quality of the high yield index, the quality is so much greater than what it has been in the past. So I do think from a fundamental aspect, there's not as much fundamental volatility within the panels and the balance sheets of high yield companies. And as Chad had mentioned earlier, we just went through COVID. When you think about management teams, we're very defensive. From March 2020 upwards to basically summer of 2021, the liquidity levels on balance sheets are still at historically high levels. So there is a lot of defensive ability within these balance sheets on top of a lower volatility from just a high level perspective. And then also looking backwards for a couple of decades to prove the point on a higher quality high yield index, you know, you've seen margins drift higher over time. And CapEx requirements drift lower while leverage levels has basically stayed at roughly the same level. So when it comes to cash flow conversion and the ability to service debts, high yields, it's an extremely good spot. And then as Fed raises rates over time, high yield issuers do have fairly low floating rate exposure overall. And so their direct impact to the channel is less than the leveraged loan issuers themselves. So that ability to service that debt is just extended longer until they actually end up having to refi, refi their debt. And I'm touching on kind of that refi wall is like the last kind of four or five years. High yield companies have really used this low rate environment to push out maturities. So we don't have a lot of near-term maturities that companies have to deal with. Now Higher rates and higher economic volatility, pressure on margins that will impact on the margin, the high yield companies. But that's where active management comes into play and where basically solid fundamental analysis, picking good companies, you'll have good returns with significantly less risk. When you look at the defaults environment, you know, it tends to really be driven by the CCC exposure in. And the index where, we just philosophic kind of run a little bit lower triple C's and take that CCC exposure when it makes sense to do so.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Harbor Health to buy 27 Village Medical clinics in Greater Houston

Harbor Health to buy 27 Village Medical clinics in Greater Houston

Harbor Health's purchase of Village Medical clinics in Houston is expected to close at the end of 2026. The 27 clinics are the primary care home for Harbor members in four counties.

  • 01Harbor's $0 specialist benefit only applies when a Harbor clinician makes the referral. For Houston employers, the test is whether employees will use the 27 clinics as their first stop.

Oct 8, 2026

SCI recruits funeral sales as the career AI cannot replace

SCI recruits funeral sales as the career AI cannot replace

SCI's recruiting video positions funeral and cremation sales as a career resistant to automation by emphasizing the human trust required in end-of-life planning. The pitch frames the role as requiring both compassion and sales drive, targets people outside the industry, and leans on demographic demand from an aging population to argue for job stability.

  • 01More than 11,000 Americans turn 65 daily, SCI says demand will grow.
  • 02SCI seeks candidates with dual traits: compassion and empathy alongside sales-oriented drive and tenacity.
  • 03The role requires no prior industry experience; SCI provides training, coaching, and technology to prepare newcomers.

Oct 7, 2026

CURORI Details Readiness Framework for Planned Ten-City Expansion in China

CURORI, a China-based medical-aesthetic coordination platform founded in 2025, has outlined a readiness framework to expand its city coverage from five to ten Chinese destinations by the end of 2027. The expansion will be phased around provider and service readiness rather than destination count alone, with review areas including qualified doctors, licensed institutions, procedure categories, communication processes, and practical factors for international users.

  • 01CURORI plans to expand from five currently served cities (Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou) to ten by December 31, 2027, with Chengdu, Xi'an, Wuhan, and two additional locations under evaluation.
  • 02The company's readiness framework requires operational checks across provider qualifications, licensed institutions, procedure availability, assessment requirements, communication processes, quotation clarity, appointment coordination, and follow-up arrangements before launching in new cities.
  • 03CURORI has a separate objective to help reduce client costs by approximately 10% by the end of 2026 through comparison, clearer quotation information, free initial coordination, and future incentives.

Oct 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512